Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults
Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890…
BioMarin Announces Proposed Private Offering of Senior Notes and Launch of New Senior Secured Term Loan Facility
BioMarin Moves to Strengthen BalanceBioMarin Announces Proposed Private Offering of Senior Notes and New Senior Secured Term Loan Syndication BioMarin Pharmaceutical Inc. announced today that it intends to offer, subject…
WuXi Biologics, HanchorBio Partner on Next-Gen Fusion Proteins
WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc.…
Bayer to Unveil New Phase III Data and Radiology Portfolio Innovations at ECR 2026
Bayer to Showcase New Phase III Data and Innovations in Radiology Portfolio at ECR 2026 Bayer will present advancements of its comprehensive radiology portfolio at the 2026 European Congress of…
GSK’s RSV Vaccine, Arexvy, Gains European Approval for Use in All Adults Aged 18 and Older
GSK’s RSV Vaccine, Arexvy, Gains European Approval for Use in All Adults Aged 18 and Older GSK plc today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy,…
Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma
Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate…
Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Therapies for Diabetes
Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Diabetes Therapies Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop…
Lilly’s Mirvetuximab Soravtansine Earns FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer
Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation…
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001 Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company,…
Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases
Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic…
Bristol Myers Squibb Partners with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection
Bristol Myers Squibb Teams Up with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection Bristol Myers Squibb, a global leader in oncology, today announced an agreement with Microsoft, a market…
Moderna & Merck: 5-Year Data Show Sustained RFS Benefit with Intismeran + KEYTRUDA® in High-Risk Melanoma
Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck…